Prognostic significance of minimal residual disease (MRD) in children with high risk acute lymphoblastic leukemia(ALL). A children's oncology group study.

被引：1
|
作者：
Borowitz, MJ
Devidas, M
Bowman, WP
Larsen, E
Pullen, J
Camitta, B
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD USA
[2] Childrens Oncol Grp, Ctr Data, Gainesville, FL USA
[3] Cook Childrens Hosp, Ft Worth, TX USA
[4] Maine Childrens Canc Program, Scarborough, ME USA
[5] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA
[6] Midw Childrens Canc Ctr, Milwaukee, WI USA
[7] Childrens Oncol Grp, Arcadia, CA USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.85.85
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
85
引用
收藏
页码：29A / 29A
页数：1
相关论文
共 50 条
  • [21] Comparison of polymerase chain reaction (PCR) and flow cytometry (FC) for the detection of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL): A pediatric oncology group study.
    Viswanatha, DS
    Bartolo, C
    Chen, IM
    Camitta, B
    Pullen, J
    Willman, CL
    Borowitz, M
    BLOOD, 2000, 96 (11) : 314A - 314A
  • [22] MINIMAL RESIDUAL DISEASE (MRD) STRONGLY PREDICTS CLINICAL OUTCOME IN A REGIMEN COMBINING BORTEZOMIB WITH REINDUCTION CHEMOTHERAPY FOR FIRST RELAPSE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A CHILDREN'S ONCOLOGY GROUP (COG) STUDY
    Horton, Terzah
    Lu, Xiaomin
    O'Brien, Maureen
    Borowitz, Michael
    Devidas, Meenakshi
    Raetz, Elizabeth
    Brown, Patrick
    Zeng, Hui
    Whitlock, James
    Hunger, Stephen
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S16 - S16
  • [23] The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) protocol AALL0433.
    Lew, Glen
    Lu, Xiaomin
    Yanofsky, Rochelle
    Rheingold, Susan R.
    Whitlock, James
    Gulig, Scott D.
    Devidas, Meenakshi
    Pulsipher, Michael
    Hastings, Caroline Aimee
    Winick, Naomi Joan
    Carroll, William L.
    Borowitz, Michael J.
    Hunger, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] MINIMAL RESIDUAL DISEASE BY MFC IN ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN
    Buldini, B.
    Varotto, E.
    Basso, G.
    HAEMATOLOGICA, 2018, 103 : S1 - S2
  • [25] Risk-adapted therapy for children with acute lymphoblastic leukemia (ALL): The children's oncology group (COG) approach
    Carroll, W. L.
    Hunger, S. P.
    Borowitz, M. J.
    Bhojwani, D.
    Willman, C. L.
    Devidas, M.
    Schultz, K.
    Loh, M. L.
    Raetz, E. A.
    ANNALS OF HEMATOLOGY, 2008, 87 : S42 - S44
  • [26] PROGNOSTIC SIGNIFICANCE OF MLL FUSION GENE TRANSCRIPTS (FGT) MONITORING AS MARKER OF MINIMAL RESIDUAL DISEASE (MRD) IN INFANT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Tsaur, Grigory
    Popov, Alexander
    Nasedkina, Tatyana
    Kalennik, Olga
    Kustanovich, Anatoly
    Aleinikova, Olga
    Riger, Tatyana
    Demina, Anna
    Streneva, Olga
    Solodovnikov, Alexander
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1026 - 1026
  • [27] Augmented Consolidation Therapy Based on Minimal Residual Disease (MRD) and Analysis of the Measurement of Sequential MRD in Childhood Acute Lymphoblastic Leukemia : Children's Cancer and leukemia Study Group of JAPAN (CCLSG), Cclsg ALL 2004 Protocol Study
    Watanabe, Arata
    Hori, Toshinori
    Shimomura, Yasuto
    Imai, Chihaya
    Ogawa, Atsushi
    Chin, Motoaki
    Shichino, Hiroyuki
    Horikoshi, Yasuo
    Nomura, Keiko
    Saikawa, Yutaka
    Yokota, Shouhei
    Inoue, Akiko
    Taga, Takashi
    Okada, Masahiko
    Ueyama, Jun-ichi
    Iwai, Asayuki
    Yano, Michihiro
    Okamoto, Yasuhiro
    Tsurusawa, Masahito
    Kikuta, Atsushi
    BLOOD, 2015, 126 (23)
  • [28] Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia A Children's Oncology Group Study
    Bhatia, Smita
    Landier, Wendy
    Hageman, Lindsey
    Chen, Yanjun
    Kim, Heeyoung
    Sun, Can-Lan
    Kornegay, Nancy
    Evans, William E.
    Angiolillo, Anne L.
    Bostrom, Bruce
    Casillas, Jacqueline
    Lew, Glen
    Maloney, Kelly W.
    Mascarenhas, Leo
    Ritchey, A. Kim
    Termuhlen, Amanda M.
    Carroll, William L.
    Wong, F. Lennie
    Relling, Mary V.
    JAMA ONCOLOGY, 2015, 1 (03) : 287 - 295
  • [29] THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    Samra, A.
    Kamel, M.
    El Sharkawy, M.
    El Fatah, M. Abd
    Ghaleb, M.
    Kamel, M.
    Abdelhamid, Th.
    Elemary, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 564 - 564
  • [30] Minimal Residual Disease (MRD) Predicts Outcomes in KMT2A-Rearranged But Not KMT2A-Wild Type Infant Acute Lymphoblastic Leukemia (ALL): AALL0631, A Children's Oncology Group Study
    Brown, P.
    Kairalla, J.
    Hilden, J.
    Dreyer, Z.
    Carroll, A.
    Heerema, N. A.
    Devidas, M.
    Carroll, W.
    Raetz, E.
    Loh, M.
    Hunger, S.
    Borowitz, M.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S28 - S29
12345